Home › Sickle Cell Disease › NCT07177300
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
Who can join
6 Months · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of sickle cell anemia (HbSS) or sickle-β0-thalassemia (HbSβ0) * Age 6 months at the time of enrollment * Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy Exclusion Criteria: * Current treatment with regularly scheduled blood transfusions * Sickle-hemoglobin C disease (HbSC), sickle-β+-thalassemia (HbSβ+)
About the study
The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA.
In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.
What is being tested
- PK-optimized oral hydroxyurea at MTD until 15 years of age. (drug)
Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 50 · Started: Dec 19, 2024
Contact the study team
- Wendi L. Long, Sr. Regulatory Specialist, BS, CCRC · Phone: 513-803-3064
- Teresa Latham, Research Director, DrPH · Phone: (513) 803-7922
Official record on ClinicalTrials.gov — NCT07177300
Locations in the U.S.
| Ohio | Cincinnati Children's Hospital Medical Center, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.